drugset / Trial / NCT00574912

Characteristics of Glargine in Type 2 Diabetics

NCT00574912

NaSingle-groupOpen-labelTreatment

Summary

The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes will show differing effects on endogenous glucose production, glucose disposal and carbohydrate and lipid flux.

Timeline

Start
2007-03
Primary completion
2009-09
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic 0.5 iu/kg Subcutaneous
Subject insulin glargine Protein / enzyme biologic 1 iu/kg Subcutaneous
Subject insulin glargine Protein / enzyme biologic 1.5 iu/kg Subcutaneous
Subject insulin glargine Protein / enzyme biologic 2 iu/kg Subcutaneous